NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
21 hedge funds and large institutions have $301K invested in NeuBase Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 7 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
22% less funds holding
Funds holding: 27 → 21 (-6)
72% less capital invested
Capital invested by funds: $1.08M → $301K (-$780K)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$15.2K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.65K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$466 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$4 |
| 5 |
Morgan Stanley
New York
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$311K |
| 2 |
DCMIC
Decheng Capital Management III (Cayman)
Grand Cayman,
Cayman Islands
|
-$92.5K |
| 3 |
Renaissance Technologies
New York
|
-$24K |
| 4 |
CM
CM Management
Gulf Breeze,
Florida
|
-$11K |
| 5 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$9.22K |
NBSE Hedge Fund Activity: Q3 2023 in Review
21 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2023, worth a combined $301K — down 72% from $1.08M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NBSE and 1 opened new positions — a net loss of 6 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $15.2K. The largest seller was Armistice Capital, exiting entirely with an estimated $311K sold.
- 21 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2023, down from 27 in Q2 2023.
- Funds reported $301K of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2023, down 72% quarter-over-quarter.
- 1 fund opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2023 and 7 closed out, a net change of -6 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2023 was Two Sigma Securities, an estimated $15.2K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2023 was Armistice Capital, an estimated $311K sold.
Based on aggregated 13F filings for Q3 2023.